Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer

Oncology Letters

Volumn 15, Issue 2, 2018, Pages 1789-1798

  Chen, Yin Ju ^a,b,c   Kuo, Chia Chun ^a   Ting, Lai Lei ^a   Lu, Long Sheng ^a,b,c   Lu, Ya Ching ^d   Cheng, Ann Joy ^d   Lin, Yun Tien ^c   Chen, Chien Ho ^c   Tsai, Jo Ting ^e,f   Chiou, Jeng Fong ^a,c,e  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cancer stem cells; Chemosensitivity; Epithelial mesenchymal transition; Oral cancer; Piperlongumine; Radiosensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 18; FLUOROURACIL; OCTAMER TRANSCRIPTION FACTOR 4; PIPERLONGUMINE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION ASSAY; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; MALE; MICROSCOPY; MOUSE; MOUTH CANCER; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING ASSAY;

EID: 85038438080     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.7486     Document Type: Article

References (53)

1. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007.
2. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
3. Rich JN: Cancer stem cells in radiation resistance. Cancer Res 67: 8980-8984, 2007.
4. Khan IN, Al-Karim S, Bora RS, Chaudhary AG and Saini KS: Cancer stem cells: A challenging paradigm for designing targeted drug therapies. Drug Discov Today 20: 1205-1216, 2015.
5. Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell 127: 679-695, 2006.
6. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
7. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
8. Sampieri K and Fodde R: Cancer stem cells and metastasis. Semin Cancer Biol 22: 187-193, 2012.
9. Scheel C and Weinberg RA: Cancer stem cells and epithe-lial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 22: 396-403, 2012.
10. Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde L, Abal M and López-López R: A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer 135: 2633-2643, 2014.
11. Warnakulasuriya S: Global epidemiology of oral and oropharyn-geal cancer. Oral Oncol 45: 309-316, 2009.
12. Huang SH and O'Sullivan B: Oral cancer: Current role of radio-therapy and chemotherapy. Med Oral Patol Oral Cir Bucal 18: e233-e240, 2013.
13. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF, Lin CJ, Hsieh LL and Cheng AJ: A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 35: 591-596, 2002.
14. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the betel quid chewing area: Recent advances in molecular carcinogenesis. Cancer Sci 99: 1507-1514, 2008.
15. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ and Yen TC: Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 15: 915-922, 2008.
16. Lee W, Yoo H, Kim JA, Lee S, Jee JG, Lee MY, Lee YM and Bae JS: Barrier protective effects of piperlonguminine in LPS-induced inflammation in vitro and in vivo. Food Chem Toxicol 58: 149-157, 2013.
17. Yao L, Chen HP and Ma Q: Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells. Immunol Lett 161: 76-80, 2014.
18. Son DJ, Kim SY, Han SS, Kim CW, Kumar S, Park BS, Lee SE, Yun YP, Jo H and Park YH: Piperlongumine inhibits athero-sclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem Biophys Res Commun 427: 349-354, 2012.
19. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, et al: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011.
20. Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER and Costa-Lotufo LV: Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci 48: 453-463, 2013.
21. Randhawa H, Kibble K, Zeng H, Moyer MP and Reindl KM: Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro 27: 1626-1633, 2013.
22. Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, et al: Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 34: 1341-1353, 2015.
23. Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, et al: Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J Cancer Res Clin Oncol 140: 2039-2046, 2014.
24. Roh JL, Kim EH, Park JY, Kim JW, Kwon M and Lee BH: Piperlongumine selectively kills cancer cells and increases cispl-atin antitumor activity in head and neck cancer. Oncotarget 5: 9227-9238, 2014.
25. Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S: Piperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Apoptosis 19: 1148-1164, 2014.
26. Wang XQ, Wang YC, Guo YT and Tang X: Effect of piperlongumine on drug resistance reversal in human retinoblastoma HXO-RB44/VCR and SO-Rb50/CBP cell lines. Int J Clin Exp Pathol 8: 2525-2534, 2015.
27. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.
28. Shostak K and Chariot A: NF-κB, stem cells and breast cancer: The links get stronger. Breast Cancer Res 13: 214, 2011.
29. Matsuda K, Sato A, Okada M, Shibuya K, Seino S, Suzuki K, Watanabe E, Narita Y, Shibui S, Kayama T and Kitanaka C: Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. Sci Rep 2: 516, 2012.
30. Lu YC, Chen YJ, Wang HM, Tsai CY, Chen WH, Huang YC, Fan KH, Tsai CN, Huang SF, Kang CJ, et al: Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila) 5: 665-674, 2012.
31. Chen CY, Lin YS, Chen CL, Chao PZ, Chiou JF, Kuo CC, Lee FP, Lin YF, Sung YH, Lin YT, et al: Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma. Oncotarget 29: 26946-26959, 2015.
32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
33. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YC, Li YL, Chiou JF and Cheng AJ: DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEFMyc/cyclin D1/MMP signaling pathway. PLoS One 8: e64088, 2013.
34. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, Zhang Y, Ling EA, Gao J and Hao A: Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 59: 763-775, 2011.
35. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JT and Cheng AJ: Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype. Cancer Gene Ther 20: 606-615, 2013.
36. Brabletz T: EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell 22: 699-701, 2012.
37. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
38. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956, 2005.
39. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, et al: The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38: 431-440, 2006.
40. Tsai LL, Yu CC, Chang YC, Yu CH and Chou MY: Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 40: 621-628, 2011.
41. Ling GQ, Chen DB, Wang BQ and Zhang LS: Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. Oncol Lett 4: 1264-1268, 2012.
42. Niwa H, Burdon T, Chambers I and Smith A: Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT 3. Genes Dev 12: 2048-2060, 1998.
43. Do DV, Ueda J, Messerschmidt DM, Lorthongpanich C, Zhou Y, Feng B, Guo G, Lin PJ, Hossain MZ, Zhang W, et al: A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev 27: 1378-1390, 2013.
44. Siu A, Lee C, Dang D and Ramos DM: Stem cell markers as predic-tors of oral cancer invasion. Anticancer Res 32: 1163-1166, 2012.
45. Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ, Wu WZ and Ren ZG: Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. J Hematol Oncol 8: 23, 2015.
46. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA and Ellis LM: Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med 1: 5-16, 2012.
47. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, et al: Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148: 1015-1028, 2012.
48. Yasui K, Shimamura M, Mitsutake N and Nagayama Y: SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell-like properties in aldehyde dehydroghenase-negative thyroid cancer cells. Thyroid 23: 989-996, 2013.
49. Masui T, Ota I, Yook JI, Mikami S, Yane K, Yamanaka T and Hosoi H: Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int J Oncol 44: 693-699, 2014.
50. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783, 2009.
51. Yao JX, Yao ZF, Li ZF and Liu YB: Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. Asian Pac J Cancer Prev 15: 3211-3217, 2014.
52. Han JG, Gupta SC, Prasad S and Aggarwal BB: Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IkappaBalpha kinase, leading to suppression of NF-κB-regulated gene products. Mol Cancer Ther 13: 2422-2435, 2014.
53. Kang Q and Yan S: Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells. Exp Ther Med 9: 1345-1350, 2015.